Forgot password?
Sign up today and your first download is free.

Rx Drugs

February 01, 2002 | Daily News

In a major new development, the House Ways and Means Committee is expected to put the drug industry's multi-billion dollar advertising and marketing practices under the microscope this year as part of its efforts to pass a Medicare prescription drug benefit and reform package.

The committee is likely to focus on the direct-to-consumer (DTC) advertising of drug companies, and examine how pharmaceuticals are bought to the market. The scrutiny of the drug industry's advertising habits is a significant new focus in the Medicare reform debate, according to health care experts.

January 31, 2002 | Daily News

In an attempt to significantly enhance patient access to prescription drugs, HHS has approved a "radical" Illinois waiver request and crafted a Medicaid model program that administration officials say will provide states with a roadmap for delivering more cost-effective drug coverage.

January 31, 2002 | Daily News

A key beneficiary group will push harder this year for the inclusion of generics as part of a Medicare prescription drug benefit and also plans to educate its members on the benefits of generics. But the lobbying effort is expected to be fiercely opposed by brand-name manufacturers, who have already floated a document that criticizes the widespread use of generic drugs.

This showdown between AARP and certain drug manufacturers could play a key role in this year's debate on adding a prescription drug benefit to Medicare.

January 30, 2002 | Daily News

In a flurry of new proposals, the White House this week announced proposals to enhance prescription drug coverage for Medicaid beneficiaries, to increase Medicare+Choice funding, and to create two Medigap plans. The initiatives are aimed at providing immediate benefits to seniors as policymakers continue to seek a consensus approach on Medicare reform.

January 30, 2002 | Daily News

Two Senate Finance Committee Democrats are strongly objecting to speculation recently floated by a powerful pharmaceutical trade group that they are close to endorsing the "tripartisan" Medicare reform proposal that is favored by the Bush administration.

January 23, 2002 | Daily News

A Medicare advocacy group is calling for a congressional probe of drug pricing policies following the launch of a new drug discount card for Medicare beneficiaries by a leading pharmaceutical manufacturer.

The Pfizer Inc. initiative should be a "wake-up call" for Congress and the administration to explore why pharmaceutical companies are not offering discounts to all Americans, says Medicare Rights Center (MRC) President Robert Hayes.